BMS strikes back against Merck in EU oesophageal cancer marketMerck & Co’s Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment Share XBMS strikes back against Merck in EU oesophageal cancer markethttps://pharmaphorum.com/news/bms-strikes-back-against-merck-in-eu-oesophageal-cancer-market/
BMS’ Catherine Owen: Hybrid communication is here to stayThe company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of Share XBMS’ Catherine Owen: Hybrid communication is here to stayhttps://deep-dive.pharmaphorum.com/magazine/communications-and-commercialisation/bristol-myers-squibb-bms-catherine-owen/
Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewPatients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo Share XScotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewhttps://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/
Failed IBD trial dents confidence in BMS’ deucravacitinibBristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) Share XFailed IBD trial dents confidence in BMS’ deucravacitinibhttps://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/
Rumour mill says Acceleron is speeding towards $11bn saleUS biopharma company Acceleron is the next company heading for a takeover by a big pharma group – Share XRumour mill says Acceleron is speeding towards $11bn salehttps://pharmaphorum.com/news/rumour-mill-says-acceleron-is-speeding-towards-11bn-sale/
Real-world study suggest AI may improve atrial fibrillation screeningAn artificial intelligence algorithm already shown to be able to detect atrial fibrillation (AF) in clinical testing has Share XReal-world study suggest AI may improve atrial fibrillation screeninghttps://pharmaphorum.com/news/real-world-study-suggest-ai-may-improve-atrial-fibrillation-screening/
Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T caseGilead Sciences’ Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Share XAppeals court reverses $1.2bn judgment against Gilead in BMS CAR-T casehttps://pharmaphorum.com/news/appeals-court-reverses-1-2bn-judgment-against-gilead-in-bms-car-t-case/
BMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyBristol Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer Share XBMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-opdivo-as-first-adjuvant-bladder-cancer-therapy/
BMS buys into AI-designed immune drug from ExscientiaBristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Share XBMS buys into AI-designed immune drug from Exscientiahttps://pharmaphorum.com/news/exscientia/
